Beam Therapeutics Inc. 8-K

What Happened
Beam Therapeutics Inc. announced the voting results from its 2026 annual meeting of stockholders held June 3, 2026 (reported on Form 8-K filed June 8, 2026). Three Class III directors were elected to serve until the 2029 annual meeting: John Evans, John Maraganore, Ph.D., and Christi Shaw. Stockholders also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal year 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers. The report was signed by CEO John Evans.

Key Details

• Director elections (serve until 2029 annual meeting):
  • John Evans: For 71,684,417; Against 864,042; Abstentions 256,889; Broker non-votes 13,419,659.
  • John Maraganore, Ph.D.: For 64,846,080; Against 7,701,591; Abstentions 257,677; Broker non-votes 13,419,659.
  • Christi Shaw: For 65,652,959; Against 6,893,102; Abstentions 259,287; Broker non-votes 13,419,659.
• Auditor ratification: Deloitte & Touche LLP ratified for fiscal year ending Dec 31, 2026 — For 85,754,272; Against 165,746; Abstentions 304,989.
• Say-on-pay (advisory): Compensation of named executive officers approved — For 71,546,749; Against 985,066; Abstentions 273,533; Broker non-votes 13,419,659.

Why It Matters
These results confirm the company’s board composition and governance choices for the coming term and maintain continuity with the re-election of the named directors. Ratification of Deloitte & Touche LLP establishes the auditor for fiscal 2026, and the advisory approval of executive compensation (say-on-pay) signals stockholder support for the company’s pay practices as presented in the proxy. Investors monitoring governance matters, board continuity, and auditor engagements can treat these items as finalized per the filed 8-K.